Ann Arbor, Mich.

Went public 8/10/2000 at $9 per share

Filing Range: 6 mil. shares @ $8 to $10

Shares Outstanding: 24 mil. shares

Underwriters: Roberston Stephens & Co./Chase H&Q/U.S. Bancorp Piper


Company Counsel: Morgan Lewis & Bockius

Manager Counsel: Testa Hurwitz & Thibeault

Auditor: Arthur Andersen & Co.

The Company:

Develops therapeutics for patients with atherosclerosis and related metabolic disorders. The company focuses on discovering new therapies in hope of treating metabolic diseases like strokes, obesity, diabetes and Alzheimer’s.

Venture Backers:

TL Ventures

Oak Investment Partners

Canaan Partners

Avalon Investments Inc.

Scheer & Co.

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 07/01/19983 Early Stage500.0

2 08/12/19984 Early Stage14500.0

3 01/18/20007 Expansion 21425.0

4 02/08/20001 Later Stage5000.0


(Data in $ millions)



Total Revenues: $0.0

Net Income: -10.7